Precision Bioprocess Engineering for Regenerative Medicine

再生医学精密生物工艺工程

• 批准号: RGPIN-2017-04124
• 负责人: Kallos, Michael
• 金额: $ 2.4万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=709972
• 关键词: Precision; Bioprocess; Engineering; Regenerative; Medicine

Regenerative medicine is a rapidly growing billion-dollar multidisciplinary field at the intersection of medicine, engineering and science. It aims to create living, functional tissues that can repair or replace damaged, diseased or aging tissues or organs. Stem cells are critical to the success of regenerative medicine therapies. What are needed are technologies to bridge the gap between basic biology and the clinical application of stem cells. One of the major stumbling blocks on the road to effective use of stem cells is the limited number of available donor cells, and the small-scale, labour-intensive methods for culturing and differentiating them. The overall goals of the proposed stem cell bioengineering research program are to develop bioreactor technologies, biomaterials and mathematical models, which will address major technology bottlenecks currently limiting the translation of stem cell discovery into improved health for Canadians. Specifically, this Discovery Grant will research the development of robust bioprocesses to generate sufficient numbers of stem cells and their differentiated progeny for multiple applications. Specific outcomes include: 1) Quantitative stem cell bioprocess computer models, resulting in better predictions of bioreactor performance (essential for bioprocess reproducibility). 2) New microcarrier and tissue engineered material designs (essential for effective growth and differentiation. 3) New technologies for high-throughput stem cell bioprocess design (essential for accelerated discovery). The long-term outcomes include innovative bioprocess designs, as well as critical knowledge of how output cell product parameters (i.e. cell type, behaviour) are influenced by cell processing parameters (i.e. bioreactor oxygen level). This is a critical next step to personalized treatments for conditions such as burns, fractures, and other ailments, and represents an opportunity for Canada to be a leader in biomanufacturing for the regenerative medicine industry.

再生医学是在医学，工程和科学的交叉点上快速增长的十亿美元多学科领域。它旨在创建可以修复或替代受损，患病或衰老的组织或器官的活性组织。干细胞对于再生医学疗法的成功至关重要。 需要的是弥合基本生物学与干细胞临床应用之间差距的技术。有效使用干细胞的道路上的主要绊脚石之一是可用的供体细胞数量有限，以及用于培养和区分它们的小规模，劳动密集型方法。拟议的干细胞生物工程研究计划的总体目标是开发生物反应器技术，生物材料和数学模型，该技术将解决目前将干细胞发现转化为加拿大人改善健康的主要技术瓶颈。具体而言，这项发现赠款将研究稳健的生物过程的开发，以生成足够数量的干细胞及其分化的后代，以用于多种应用。具体结果包括：1）定量的干细胞生物处理计算机模型，从而更好地预测了生物反应器性能（对于生物普罗森特重复性必不可少）。 2）新的微载体和组织工程材料设计（对于有效的生长和分化至关重要。3）新技术用于高通量干细胞生物过程设计（对于加速发现至关重要）。长期结局包括创新的生物普应设计，以及有关输出细胞产物参数（即细胞类型，行为）如何受细胞加工参数（即生物反应器氧水平）影响的关键知识。这是针对诸如烧伤，裂缝和其他疾病等疾病的个性化治疗方法的关键下一步，并且为加拿大成为再生医学行业生物制造领域的领导者是一个机会。